MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Clinical trials for MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Vitamin d boost may extend life in lymphoma patients, trial hopes
Disease control OngoingThis study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…
Matched conditions: MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: NA • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to boost remission in tough lymphoma
Disease control TerminatedThis phase II trial tests whether adding either duvelisib or oral azacitidine to standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma that have not been treated yet. About 170 participants will receive one of three treatment combinat…
Matched conditions: MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Gene therapy takes on HIV and cancer in one shot
Disease control OngoingThis early-phase trial tests a gene therapy approach for people with HIV who also have lymphoma that has returned or not responded to treatment. Researchers take the patient's own stem cells, add anti-HIV genes in the lab, and return them after a stem cell transplant. The goal is…
Matched conditions: MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo shows promise against tough lymphoma
Disease control OngoingThis phase 2 trial tests a new combination treatment for a rare type of lymphoma (CD30-positive peripheral T-cell lymphoma). It combines a targeted drug (brentuximab vedotin) with standard chemotherapy. The goal is to see if this approach improves the number of patients who achie…
Matched conditions: MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC